Tag: results

Ekopak (EKOP:xbru), a company specialized in circular water solutions, announces the appointment of Jean-Baptiste De Cuyper as its new CEO. This appointment follows the earlier communication of May 12, 2025, in which the company announced its intention to appoint an external candidate for this key role. The appointment is part of Ekopak's broader efforts to strengthen its governance and management structure.

Fiscal Year 2025 Earnings

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

In 2025 Q2, 3.5 million tons of cargo and 2.2 million passengers passed through the harbours of Tallinna Sadam. Compared to the same period previous year, the number of passengers increased by 3.8% i.e. 81 thousand passengers. Cargo volumes increased 8% i.e. 253 thousand tons. The number of vessel calls increased by 2.1%. The number of passengers travelling between the Estonian mainland and the main islands increased by 2.4%, the number of vehicles increased by 3.4%. The number of charter days of the icebreaker Botnica declined 63% comparing to last year.

ATLANTA, July 08, 2025 (GLOBE NEWSWIRE) -- Gray Media, Inc. (“Gray”) (NYSE: GTN) announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 9.625% senior secured second lien notes due 2032 (the “Notes”). This represents an increase of $150 million over the amount previously announced. The Notes were priced at 100% of par. The offering of the Notes is expected to close on July 18, 2025, subject to customary closing conditions.

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.

Singapore, July 08, 2025 (GLOBE NEWSWIRE) -- Delixy Holdings Limited (the “Company” or “Delixy”), a Singapore-based company engaged in the trading of oil related products, today announced the pricing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares, par value US$0.000005 per share, (“Ordinary Shares”), 1,350,000 of which are being offered by the Company and 650,000 by the selling shareholders Mega Origin Holdings Limited (as to 325,000 Ordinary Shares) and Novel Majestic Limited (as to 325,000 Ordinary Shares) (the “Selling Shareholders”), at a public offering price of US$4.00 per Ordinary Share. The Company is also registering a resale prospectus concurrent with the Offering for the resale of 3,000,000 Ordinary Shares held by Cosmic Magnet Limited, Rosywood Holdings Limited, Dragon Circle Limited and Novel Majestic Limited, Golden Legend Ventures Limited (the “Resale Shareholders”). The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July 9, 2025 under the ticker symbol “DLXY.”

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Semler Scientific, Inc. (NASDAQ: SMLR) resulting from allegations that Semler Scientific may have issued materially misleading business information to the investing public.

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.